Found 0 matching trials
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
NATo evaluate orelabrutinib in combination with polatuzumab vedotin, rituxima...
Location
the First Affiliated Hospital of Xiamen University
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
PHASE1This study will test polatuzumab vedotin in combination with rituximab in p...
Status
Active Not Recruiting
Location
Washington University School of Medicine
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
PHASE1The purpose of this study is to is to determine the effects (good and bad) ...
Location
University of Miami
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
PHASE2Aim of this study will evaluate the efficacy and safety of Polatuzumab Vedo...
Status
Enrolling By Invitation
Location
The First Affiliated Hospital of Soochow University
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
PHASE1This is a prospective, multicenter, open-label Phase Ib/II clinical study d...
Location
Sun Yat-sen University Cancer Center